The physiology: why breathing modulates the pulse-oximeter waveform
Every pulse oximeter records a photoplethysmography (PPG) waveform that carries both a cardiac component and a respiratory component. Inspiration changes intrathoracic pressure and venous return, which modulates stroke volume and, in turn, the amplitude and timing of the pulse. The exaggerated form of this modulation is pulsus paradoxus. PulSentry computes a pulsus index, the ratio of the respiratory spectral peak to the cardiac spectral peak, from that waveform. The question this article explores is narrow: the same respiratory modulation is physiologically meaningful in conditions other than tamponade, so is it worth studying as a more general signal of breathlessness?
Established uses of respiratory pleth variation
Acute asthma severity (the closest analog)
Pulsus paradoxus is one of the few objective bedside measures of acute asthma severity. Steele and colleagues showed that continuous, noninvasive pulsus paradoxus derived from the pleth waveform tracks exacerbation severity. Arnold, Wang and Hartert later studied a pulse-oximeter-derived measure they termed PEP in 684 children with acute asthma and found significant associations between baseline PEP and airway-resistance and symptom measures (Acad Emerg Med 2016). The signal is real and measurable from the pleth.
Fluid responsiveness: the pleth variability index (PVI), with honest limits
Respiratory variation in pulse amplitude underlies the FDA-cleared pleth variability index (PVI). In mechanically ventilated patients under general anesthesia, Cannesson and colleagues found a PVI above about 14% discriminated fluid responders with roughly 81% sensitivity and 100% specificity (n=25, Br J Anaesth 2008). The crucial caveat: PVI performs poorly in spontaneously breathing patients and those on vasopressors. This is exactly why a spectral pulsus index must be validated in its own intended population rather than inheriting PVI's numbers.
Respiratory rate
The PPG also encodes respiratory rate, and validated FFT, wavelet, and decomposition methods extract it. Abnormal respiratory rate is a well-established early-warning sign of deterioration in breathless patients.
From tamponade to broader breathlessness: the research hypothesis
Our tamponade work looks for a persistent, rising pulsus index. The dyspnea hypothesis is distinct and narrower: that the degree of respiratory modulation in the PPG carries information about the severity or course of breathlessness from other causes. To study the full severity spectrum, our collaborators have assembled a retrospective waveform set (a 100-patient subset of the MIMIC-IV critical-care database, comprising thousands of hours of recordings) to characterize the high end, alongside a prospective cohort of emergency-department patients with shortness of breath who do not have tamponade at the lower end. See how we are validating PulSentry.
What we are NOT claiming
- We are not claiming PulSentry detects, diagnoses, or rules out asthma, COPD, heart failure, or any cause of dyspnea.
- We are not claiming a cleared indication. A dyspnea use would be a new intended use requiring its own FDA submission and its own prospective validation.
- We are not importing PVI's ventilated-patient performance to spontaneously breathing patients.
- We are describing a signal under study, scoped to the evidence above.
Why the regulatory framing matters
Under FDA guidance, adding a new disease, condition, or patient population is a major change in intended use. PulSentry's tamponade work and any future dyspnea work are therefore separate claims, each needing its own evidence and submission. The responsible path is a pre-submission conversation with the FDA before committing to a dyspnea intended use, and we treat this direction as a research program, not a product claim.